Trial Profile

A phase II trial investigating tipifarnib in patients with HRAS mutant relapsed or refractory urothelial cancer

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 03 Jun 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tipifarnib (Primary)
Indications Urogenital cancer
Focus Proof of concept; Therapeutic Use

Most Recent Events

29 May 2020 Results presented in the Kura Oncology Media Release.
05 Nov 2019 According to a Kura Oncology media release, data from this study is expected to be presented at a medical meeting next year(2020).
03 Sep 2019 According to a Kura Oncology media release, Se Hoon Park, M.D., Ph.D., Samsung Medical Center is the principal investigator of this trial.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com